Merck's two-drug HIV regimen doravirine/islatravir maintained viral suppression and matched Gilead's Biktarvy in Phase 3 ...
The challenge with curing the Human Immunodeficiency Virus (HIV) is that it tends to hide dormant in cells, evading the body’s natural immune system as well as some therapies. A new study uses novel ...
Currently available medications could be enough to end the HIV epidemic in the United States, provided people can access and ...
According to the new study, HIV achieves this with a tissue-specific approach, cloaking itself in a host cell's DNA by ...
Among patients with late diagnosed HIV infection, the choice of a two- or three-drug regimen is not associated with 48 week ...
A new analysis finds that generic lenacapavir, a twice-yearly HIV preventive treatment, could be mass produced for just $25 ...
Nursing home patients with HIV tend to be younger. They also typically have more comorbidities than the average patient, and ...
Gilead Sciences, Inc., GILD announced that it has entered into settlement agreements to resolve the patent litigations with a ...
After tense negotiations, Gilead Sciences has agreed not to boost prices next year for HIV medicines that are sold to state ...
HOUSTON — With President Trump's "Big, Beautiful Bil l," making major cuts to Medicaid, health care professionals and patients are warning of the potentially deadly consequences for people living with ...
Cuts proposed by the Trump administration and House Republicans could drive up new HIV cases by more than 200,000 by 2030, ...